GlaxoSmithKline Pharmaceuticals has provided the weblink for its Annual Report for the financial year ended March 31, 2026, ensuring compliance with Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholders whose email addresses are registered with the Depository Participants or Registrar and Transfer Agent (RTA) have already received the report via email. For those without registered email addresses, the company has issued a formal letter containing the specific web-link to access the document online.

The company emphasized that it is mandatory for all shareholders, including joint holders, to update their PAN, KYC details, and nomination information. This update must include postal address with pin code, email address, mobile number, and bank account details. Shareholders are required to submit the necessary documents and information to their respective Depository Participant or RTA at the earliest.

Failure to update these details will have direct financial consequences. The company stated that any payments, including dividends, for folios where PAN or KYC details are not updated will be withheld. These payments will only be made electronically once the required information is registered with the authorities.

Shareholder Support Services

To assist investors, the company highlighted the Senior Citizens Investor Cell established by its RTA, Kfintech Technologies Limited. This service is exclusively designed to assist shareholders above the age of 60 with redressing grievances, complaints, and queries. Senior citizens can contact the cell via email at senior.citizen@kfintech.com or call the dedicated toll-free number 1800 3094 006.

The Annual Report for FY26 is available at: https://india-pharma.gsk.com/en-in/investors/annual-reports/ . Shareholders facing further queries or requiring assistance are advised to contact the RTA at inward.ris@kfintech.com .

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE159A01016/f7fb66470a7a4bfa.pdf

GlaxoSmithKline Pharmaceuticals Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for FY26 to BSE Limited and the National Stock Exchange of India Limited. The filing, made on June 5, 2026, details the company's performance on environmental, social, and governance parameters. The report, which forms part of the Annual Report, has undergone reasonable assurance by Bureau Veritas India Pvt. Ltd.

The company reported a Corporate Social Responsibility (CSR) expenditure of ₹1,859.48 Lakhs for the financial year. This spending represents 2% of the average net profit from the previous three financial years. The initiatives reached over 60,000 beneficiaries, focusing on healthcare infrastructure and quality education for underprivileged communities.

Environmental Performance

GlaxoSmithKline Pharmaceuticals achieved a reduction in its environmental footprint during the year. Total greenhouse gas (GHG) emissions decreased from 10,422 tonnes of CO2 equivalent (tCO2e) in FY 2024-25 to 9,346 tCO2e in FY 2025-26, a reduction of 10.32%. The Nashik manufacturing site generated 495.61 MT of direct Scope 1 CO2 emissions, while Scope 2 emissions were nil due to full coverage by Renewable Energy Certificates.

Water consumption also declined significantly. The company reported total water consumption of 66,608 kilolitres (kL) in FY 2025-26, compared to 76,714 kL in the previous year, marking a 13.2% reduction. The Nashik plant successfully achieved Zero Liquid Discharge (ZLD) by recycling 100% of treated process effluent.

Operational and Employee Metrics

The company’s total workforce comprised 1,507 employees and 1,623 workers as of the end of the financial year. Women constituted 16.79% of the total employees and 10.47% of the total workers. The Board of Directors included 7 members, with female representation at 29%. Key Management Personnel had a female representation of 43%.

Financial and Governance Details

The company recorded a turnover of ₹3,79,020.27 Lakhs and a net worth of ₹2,24,117.21 Lakhs. Paid-up capital stood at ₹16,940.60 Lakhs. The report confirmed that there were no fines or penalties imposed by regulators during the year, and no instances of anti-competitive conduct were identified.